Patrick L Iversen

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7232049/publications.pdf

Version: 2024-02-01

228	10,063	22153	48315
papers	citations	59 h-index	88 g-index

231	231	231	6453
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Effective rescue of dystrophin improves cardiac function in dystrophin-deficient mice by a modified morpholino oligomer. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 14814-14819.	7.1	233
2	Sustained Dystrophin Expression Induced by Peptide-conjugated Morpholino Oligomers in the Muscles of mdx Mice. Molecular Therapy, 2008, 16, 1624-1629.	8.2	230
3	Antisense oligonucleotide-induced exon skipping restores dystrophin expression in vitro in a canine model of DMD. Gene Therapy, 2006, 13, 1373-1381.	4.5	193
4	Advanced antisense therapies for postexposure protection against lethal filovirus infections. Nature Medicine, 2010, 16, 991-994.	30.7	189
5	Cellular Uptake of Antisense Morpholino Oligomers Conjugated to Arginine-Rich Peptides. Bioconjugate Chemistry, 2004, 15, 290-299.	3.6	184
6	Vectorization of morpholino oligomers by the (R-Ahx-R)4 peptide allows efficient splicing correction in the absence of endosomolytic agents. Journal of Controlled Release, 2006, 116, 304-313.	9.9	180
7	Pharmacokinetics, Biodistribution, Stability and Toxicity of a Cell-Penetrating Peptideâˆ'Morpholino Oligomer Conjugate. Bioconjugate Chemistry, 2007, 18, 1325-1331.	3.6	169
8	Cell penetrating peptide conjugates of steric block oligonucleotides. Advanced Drug Delivery Reviews, 2008, 60, 517-529.	13.7	168
9	Stability of Cell-Penetrating Peptideâˆ'Morpholino Oligomer Conjugates in Human Serum and in Cells. Bioconjugate Chemistry, 2007, 18, 50-60.	3.6	158
10	Lipoxygenase Inhibitors Abolish Proliferation of Human Pancreatic Cancer Cells. Biochemical and Biophysical Research Communications, 1999, 261, 218-223.	2.1	157
11	Inhibition of Flavivirus Infections by Antisense Oligomers Specifically Suppressing Viral Translation and RNA Replication. Journal of Virology, 2005, 79, 4599-4609.	3.4	151
12	Morpholino Oligomerâ€"Mediated Exon Skipping Averts the Onset of Dystrophic Pathology in the mdx Mouse. Molecular Therapy, 2007, 15, 1587-1592.	8.2	150
13	Cellular Uptake and Subcellular Distribution of Phosphorothioate Oligonucleotides into Cultured Cells. Antisense Research and Development, 1992, 2, 211-222.	3.1	148
14	Expression and regulation of brain metallothionein. Neurochemistry International, 1995, 27, 1-22.	3.8	146
15	Phase I trial of an antisense oligonucleotide OL(1)p53 in hematologic malignancies.. Journal of Clinical Oncology, 1996, 14, 1320-1326.	1.6	146
16	Systemic Administration of a Phosphorothioate Oligonucleotide with a Sequence Complementary to p53 for Acute Myelogenous Leukemia and Myelodysplastic Syndrome: Initial Results of a Phase I Trial. Antisense Research and Development, 1993, 3, 383-390.	3.1	138
17	Pharmacokinetics and biodistribution of phosphorodiamidate morpholino antisense oligomers. Current Opinion in Pharmacology, 2005, 5, 550-555.	3.5	137
18	Gene-Specific Countermeasures against Ebola Virus Based on Antisense Phosphorodiamidate Morpholino Oligomers. PLoS Pathogens, 2006, 2, e1.	4.7	137

#	Article	IF	Citations
19	Inhibition of dengue virus translation and RNA synthesis by a morpholino oligomer targeted to the top of the terminal 3â€² stemâ€“loop structure. Virology, 2006, 344, 439-452.	2.4	129
20	VP35 Knockdown Inhibits Ebola Virus Amplification and Protects against Lethal Infection in Mice. Antimicrobial Agents and Chemotherapy, 2006, 50, 984-993.	3.2	119
21	Review of in vivo pharmacokinetics and toxicology of phosphorothioate oligonucleotides. Journal of Clinical Laboratory Analysis, 1995, 9, 129-137.	2.1	114
22	Cell-penetrating-peptide-based delivery of oligonucleotides: an overview. Biochemical Society Transactions, 2007, 35, 775-779.	3.4	109
23	Inhibition of Dengue Virus Serotypes 1 to 4 in Vero Cell Cultures with Morpholino Oligomers. Journal of Virology, 2005, 79, 5116-5128.	3.4	108
24	Characterization of Binding Sites, Extent of Binding, and Drug Interactions of Oligonucleotides with Albumin. Antisense Research and Development, 1995, 5, 131-139.	3.1	106
25	Cell-penetrating peptides as transporters for morpholino oligomers: effects of amino acid composition on intracellular delivery and cytotoxicity. Nucleic Acids Research, 2007, 35, 5182-5191.	14.5	105
26	Discovery and Early Development of AVI-7537 and AVI-7288 for the Treatment of Ebola Virus and Marburg Virus Infections. Viruses, 2012, 4, 2806-2830.	3.3	105
27	Interaction of diagnostic ultrasound with synthetic oligonucleotide-labeled perfluorocarbon-exposed sonicated dextrose albumin microbubbles.. Journal of Ultrasound in Medicine, 1996, 15, 577-584.	1.7	102
28	Inhibition, Escape, and Attenuated Growth of Severe Acute Respiratory Syndrome Coronavirus Treated with Antisense Morpholino Oligomers. Journal of Virology, 2005, 79, 9665-9676.	3.4	102
29	In vivo Bioavailability and Pharmacokinetics of a c-MYC Antisense Phosphorodiamidate Morpholino Oligomer, AVI-4126, in Solid Tumors. Clinical Cancer Research, 2005, 11, 3930-3938.	7.0	102
30	Efficacy of antisense morpholino oligomer targeted to c-myc in prostate cancer xenograft murine model and a Phase I safety study in humans. Clinical Cancer Research, 2003, 9, 2510-9.	7.0	98
31	X-linked inhibitor of apoptosis protein inhibition induces apoptosis and enhances chemotherapy sensitivity in human prostate cancer cells. Molecular Cancer Therapeutics, 2004, 3, 699-707.	4.1	97
32	Effects of systemic multiexon skipping with peptide-conjugated morpholinos in the heart of a dog model of Duchenne muscular dystrophy. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 4213-4218.	7.1	94
33	A novel antisense inhibitor of MMP-9 attenuates angiogenesis, human prostate cancer cell invasion and tumorigenicity. Cancer Gene Therapy, 2003, 10, 823-832.	4.6	91
34	Pharmacokinetics of an Antisense Phosphorothioate Oligodeoxynucleotide against rev from Human Immunodeficiency Virus Type 1 in the Adult Male Rat Following Single Injections and Continuous Infusion. Antisense Research and Development, 1994, 4, 43-52.	3.1	89
35	West Nile virus genome cyclization and RNA replication require two pairs of long-distance RNA interactions. Virology, 2008, 373, 1-13.	2.4	88
36	HIV Tat Peptide Enhances Cellular Delivery of Antisense Morpholino Oligomers. Oligonucleotides, 2003, 13, 31-43.	4.3	86

#	Article	IF	Citations
37	In Vitro Resistance Selection and In Vivo Efficacy of Morpholino Oligomers against West Nile Virus. Antimicrobial Agents and Chemotherapy, 2007, 51, 2470-2482.	3.2	86
38	Inhibition of Human Immunodeficiency Virus Type 1-mediated Cytopathic Effects by Poly(L-lysine)-conjugated Synthetic Antisense Oligodeoxyribonucleotides. Journal of General Virology, 1989, 70, 2673-2682.	2.9	83
39	Antiviral Effects of Antisense Morpholino Oligomers in Murine Coronavirus Infection Models. Journal of Virology, 2007, 81, 5637-5648.	3.4	82
40	Inhibition of Multiple Subtypes of Influenza A Virus in Cell Cultures with Morpholino Oligomers. Antimicrobial Agents and Chemotherapy, 2006, 50, 3724-3733.	3.2	81
41	Delivery of steric block morpholino oligomers by (R-X-R)4 peptides: structure-activity studies. Nucleic Acids Research, 2008, 36, 6343-6354.	14.5	79
42	A Hexameric Phosphorothioate Oligonucleotide Telomerase Inhibitor Arrests Growth of Burkitt's Lymphoma Cellsin Vitroandin Vivo. Toxicology and Applied Pharmacology, 1997, 144, 189-197.	2.8	75
43	Antisense Phosphorodiamidate Morpholino Oligomers Targeted to an Essential Gene InhibitBurkholderia cepaciaComplex. Journal of Infectious Diseases, 2010, 201, 1822-1830.	4.0	75
44	Arginine-rich cell-penetrating peptide dramatically enhances AMO-mediated ATM aberrant splicing correction and enables delivery to brain and cerebellum. Human Molecular Genetics, 2011, 20, 3151-3160.	2.9	75
45	Cell-penetrating peptideâ€“morpholino conjugates alter pre-mRNA splicing of DMD (Duchenne muscular) Tj ETQq1 1 0.784314 rgBT /O Transactions, 2007, 35, 826-828.	3.4	74
46	Safety and Pharmacokinetic Profiles of Phosphorodiamidate Morpholino Oligomers with Activity against Ebola Virus and Marburg Virus: Results of Two Single-Ascending-Dose Studies. Antimicrobial Agents and Chemotherapy, 2014, 58, 6639-6647.	3.2	73
47	Antisense Morpholino-Oligomers Directed against the 5â€² End of the Genome Inhibit Coronavirus Proliferation and Growthâ€. Journal of Virology, 2004, 78, 5891-5899.	3.4	71
48	Inhibition of Gene Expression inEscherichia coliby Antisense Phosphorodiamidate Morpholino Oligomers. Antimicrobial Agents and Chemotherapy, 2003, 47, 3233-3239.	3.2	70
49	Bioavailability and Efficacy of Antisense Morpholino Oligomers Targeted to c-myc and Cytochrome P-450 3A2 Following Oral Administration in Rats. Journal of Pharmaceutical Sciences, 2002, 91, 1009-1018.	3.3	69
50	Neutrally Charged Phosphorodiamidate Morpholino Antisense Oligomers: Uptake, Efficacy and Pharmacokinetics. Current Pharmaceutical Biotechnology, 2004, 5, 431-439.	1.6	68
51	Antisense oligonucleotide induced exon skipping and the dystrophin gene transcript: cocktails and chemistries. BMC Molecular Biology, 2007, 8, 57.	3.0	66
52	Peptide-conjugated morpholino oligomers inhibit porcine reproductive and respiratory syndrome virus replication. Antiviral Research, 2008, 77, 95-107.	4.1	65
53	Chemical Modifications of Antisense Morpholino Oligomers Enhance Their Efficacy against Ebola Virus Infection. Antimicrobial Agents and Chemotherapy, 2009, 53, 2089-2099.	3.2	65
54	Variations in Amino Acid Composition of Antisense Peptide-Phosphorodiamidate Morpholino Oligomer Affect Potency against Escherichia coli In Vitro and In Vivo. Antimicrobial Agents and Chemotherapy, 2009, 53, 525-530.	3.2	65

#	Article	IF	Citations
55	Inhibition of Coxsackievirus B3 in Cell Cultures and in Mice by Peptide-Conjugated Morpholino Oligomers Targeting the Internal Ribosome Entry Site. Journal of Virology, 2006, 80, 11510-11519.	3.4	64
56	Gene-Silencing Antisense Oligomers Inhibit Acinetobacter Growth In Vitro and In Vivo. Journal of Infectious Diseases, 2013, 208, 1553-1560.	4.0	64
57	Induced dystrophin exon skipping in human muscle explants. Neuromuscular Disorders, 2006, 16, 583-590.	0.6	63
58	Gene structure and nucleotide sequence for rat cytochrome P-450c. Archives of Biochemistry and Biophysics, 1985, 237, 465-476.	3.0	61
59	Intramural coronary delivery of advanced antisense oligonucleotides reduces neointimal formation in the porcine stent restenosis model. Journal of the American College of Cardiology, 2002, 39, 1686-1691.	2.8	61
60	Treatment of AG129 mice with antisense morpholino oligomers increases survival time following challenge with dengue 2 virus. Journal of Antimicrobial Chemotherapy, 2008, 62, 555-565.	3.0	59
61	A Single Phosphorodiamidate Morpholino Oligomer Targeting VP24 Protects Rhesus Monkeys against Lethal Ebola Virus Infection. MBio, 2015, 6, .	4.1	59
62	Antiproliferative Effects of Steric Blocking Phosphorodiamidate Morpholino Antisense Agents Directed against c-myc. Oligonucleotides, 2000, 10, 163-176.	4.3	58
63	Gene-Specific Effects of Antisense Phosphorodiamidate Morpholino Oligomer-Peptide Conjugates on Escherichia coli and Salmonella enterica Serovar Typhimurium in Pure Culture and inTissue Culture. Antimicrobial Agents and Chemotherapy, 2006, 50, 2789-2796.	3.2	58
64	Morpholino oligomers targeting the PB1 and NP genes enhance the survival of mice infected with highly pathogenic influenza A H7N7 virus. Journal of General Virology, 2008, 89, 939-948.	2.9	57
65	Resistance to chemotherapeutic drugs overcome by c-Myc inhibition in a Lewis lung carcinoma murine model. Anti-Cancer Drugs, 2003, 14, 39-47.	1.4	56
66	Systemic Human Antisense Therapy Begins. Antisense Research and Development, 1992, 2, 109-110.	3.1	54
67	Arginine-Rich Peptide Conjugation to Morpholino Oligomers:â€‰ Effects on Antisense Activity and Specificity. Bioconjugate Chemistry, 2005, 16, 959-966.	3.6	54
68	Antisense peptide-phosphorodiamidate morpholino oligomer conjugate: dose-response in mice infected with Escherichia coli. Journal of Antimicrobial Chemotherapy, 2006, 59, 66-73.	3.0	54
69	Inhibition of influenza A H3N8 virus infections in mice by morpholino oligomers. Archives of Virology, 2008, 153, 929-937.	2.1	53
70	Antisense phosphorodiamidate morpholino oligomer inhibits viability of Escherichia coli in pure culture and in mouse peritonitis. Journal of Antimicrobial Chemotherapy, 2005, 55, 983-988.	3.0	52
71	Antisense Phosphorodiamidate Morpholino Oligomer Length and Target Position Effects on Gene-Specific Inhibition in Escherichia coli. Antimicrobial Agents and Chemotherapy, 2005, 49, 249-255.	3.2	51
72	Peptide-based delivery of nucleic acids: design, mechanism of uptake and applications to splice-correcting oligonucleotides. Biochemical Society Transactions, 2007, 35, 53-55.	3.4	51

#	Article	IF	Citations
73	Inhibition of Respiratory Syncytial Virus Infections With Morpholino Oligomers in Cell Cultures and in Mice. Molecular Therapy, 2008, 16, 1120-1128.	8.2	51
74	AVI-7288 for Marburg Virus in Nonhuman Primates and Humans. New England Journal of Medicine, 2015, 373, 339-348.	27.0	50
75	Suppression of porcine reproductive and respiratory syndrome virus replication by morpholino antisense oligomers. Veterinary Microbiology, 2006, 117, 117-129.	1.9	49
76	Selective Cytotoxicity to Human Leukemic Myeloblasts Produced by Oligodeoxyribonucleotide Phosphorothioates Complementary to p53 Nucleotide Sequences. Leukemia and Lymphoma, 1994, 12, 223-231.	1.3	48
77	Inhibition of carotid artery neointimal formation with intravenous microbubbles. Ultrasound in Medicine and Biology, 2001, 27, 259-265.	1.5	48
78	Inhibition of replication and transcription activator and latency-associated nuclear antigen of Kaposi's sarcoma-associated herpesvirus by morpholino oligomers. Antiviral Research, 2007, 73, 12-23.	4.1	47
79	Intracellular Delivery Strategies for Antisense Phosphorodiamidate Morpholino Oligomers. Oligonucleotides, 2000, 10, 263-274.	4.3	46
80	c-myc antisense oligonucleotide treatment ameliorates murine ARPKD. Kidney International, 2002, 61, S125-S131.	5.2	45
81	c-MYC antisense phosphosphorodiamidate morpholino oligomer inhibits lung metastasis in a murine tumor model. Lung Cancer, 2008, 60, 347-354.	2.0	44
82	Byâ€passing the nonsense mutation in the 4^{CV} mouse model of muscular dystrophy by induced exon skipping. Journal of Gene Medicine, 2009, 11, 46-56.	2.8	44
83	Benzimidazoisoquinolines: A New Class of Rapidly Metabolized Aryl Hydrocarbon Receptor (AhR) Ligands that Induce AhR-Dependent Tregs and Prevent Murine Graft-Versus-Host Disease. PLoS ONE, 2014, 9, e88726.	2.5	43
84	Anin vitro model for endothelial permeability: Assessment of monolayer integrity. In Vitro Cellular and Developmental Biology - Animal, 1995, 31, 846-852.	1.5	42
85	Effects of Size and Sequence on the Iontophoretic Delivery of Oligonucleotidest. Journal of Pharmaceutical Sciences, 1998, 87, 49-52.	3.3	42
86	Cationic phosphorodiamidate morpholino oligomers efficiently prevent growth of Escherichia coli in vitro and in vivo. Journal of Antimicrobial Chemotherapy, 2010, 65, 98-106.	3.0	42
87	Recent successes in therapeutics for Ebola virus disease: no time for complacency. Lancet Infectious Diseases, The, 2020, 20, e231-e237.	9.1	42
88	A Morpholino Oligomer Targeting Highly Conserved Internal Ribosome Entry Site Sequence Is Able To Inhibit Multiple Species of Picornavirus. Antimicrobial Agents and Chemotherapy, 2008, 52, 1970-1981.	3.2	41
89	Bacterial Resistance to Antisense Peptide Phosphorodiamidate Morpholino Oligomers. Antimicrobial Agents and Chemotherapy, 2012, 56, 6147-6153.	3.2	41
90	Iontophoretic delivery of a telomeric oligonucleotide. Pharmaceutical Research, 1996, 13, 851-854.	3.5	40

#	Article	IF	Citations
91	Involvement of Vacuolar Protein Sorting Pathway in Ebola Virus Release Independent of TSG101 Interaction. Journal of Infectious Diseases, 2007, 196, S264-S270.	4.0	40
92	Alternative Splicing in the Cytochrome P450 Superfamily Expands Protein Diversity to Augment Gene Function and Redirect Human Drug Metabolism. Drug Metabolism and Disposition, 2017, 45, 375-389.	3.3	40
93	Metallothionein in carcinogenesis and cancer chemotherapy. General Pharmacology, 1994, 25, 1297-1310.	0.7	39
94	Inhibition of human chorionic gonadotropin Î²â€subunit modulates the mitogenic effect of câ€myc in human prostate cancer cells. Prostate, 2002, 53, 200-210.	2.3	39
95	Antiviral activity of morpholino oligomers designed to block various aspects of Equine arteritis virus amplification in cell culture. Journal of General Virology, 2005, 86, 3081-3090.	2.9	39
96	Cholesteryl-Conjugated Phosphorothioate Oligodeoxynucleotides Modulate CYP2B1 ExpressionIn Vivo. Journal of Drug Targeting, 1995, 2, 477-485.	4.4	38
97	Advanced câ€myc antisense (AVIâ€4126)â€eluting phosphorylcholineâ€coated stent implantation is associated with complete vascular healing and reduced neointimal formation in the porcine coronary restenosis model. Catheterization and Cardiovascular Interventions, 2004, 61, 518-527.	1.7	37
98	Inhibition of alphavirus infection in cell culture and in mice with antisense morpholino oligomers. Virology, 2008, 376, 357-370.	2.4	37
99	The mechanism of inhibition of cytochrome P450IIE1 by dihydrocapsaicin. Bioorganic Chemistry, 1990, 18, 185-198.	4.1	36
100	Phosphorodiamidate Morpholino Antisense Oligomers Inhibit Expression of Human Cytochrome P450 3A4 and Alter Selected Drug Metabolism. Drug Metabolism and Disposition, 2002, 30, 757-762.	3.3	35
101	Preparation of 35S-labeled polyphosphorothioate oligodeoxyribonucleotides by use of hydrogen phosphonate chemistry. Analytical Biochemistry, 1990, 188, 11-16.	2.4	34
102	Inhibition of Foot-and-Mouth Disease Virus Infections in Cell Cultures with Antisense Morpholino Oligomers. Journal of Virology, 2007, 81, 11669-11680.	3.4	34
103	In VivoEvaluation of a Morpholino Antisense Oligomer Directed Against Tumor Necrosis Factor-Î±. Oligonucleotides, 2000, 10, 11-16.	4.3	33
104	Induction of revertant fibres in the mdx mouse using antisense oligonucleotides. Genetic Vaccines and Therapy, 2006, 4, 3.	1.5	33
105	Vesivirus viremia and seroprevalence in humans. Journal of Medical Virology, 2006, 78, 693-701.	5.0	33
106	Inhibition of Vesivirus Infections in Mammalian Tissue Culture with Antisense Morpholino Oligomers. Oligonucleotides, 2001, 11, 317-325.	4.3	32
107	ANDROGEN RECEPTOR DOWN-REGULATION IN PROSTATE CANCER WITH PHOSPHORODIAMIDATE MORPHOLINO ANTISENSE OLIGOMERS. Journal of Urology, 2004, 172, 1140-1144.	0.4	32
108	Evaluation of antisense mechanisms of action. Methods in Enzymology, 2000, 313, 135-143.	1.0	31

#	Article	IF	Citations
109	Inhibition of Intracellular Growth of Salmonella enterica Serovar Typhimurium in Tissue Culture by Antisense Peptide-Phosphorodiamidate Morpholino Oligomer. Antimicrobial Agents and Chemotherapy, 2009, 53, 3700-3704.	3.2	31
110	Transdermal delivery of antisense compounds. Advanced Drug Delivery Reviews, 2000, 44, 51-57.	13.7	30
111	Bolus Intravenous Injection of Phosphorothioate Oligonucleotides Causes Hypotension by Acting as Î±1-Adrenergic Receptor Antagonists. Toxicology and Applied Pharmacology, 1999, 160, 289-296.	2.8	29
112	Preparation and partial characterization of highly purified primary cultures of neurons and non-neuronal (glial) cells from embryonic chick cerebral hemispheres and several other regions of the nervous system. Developmental Brain Research, 1982, 3, 529-545.	1.7	28
113	Ex Vivo Treatment of Bone Marrow with Phosphorothioate Oligonucleotide OL(l)p53 for Autologous Transplantation in Acute Myelogenous Leukemia and Myelodysplastic Syndrome. Stem Cells and Development, 1997, 6, 441-446.	1.0	28
114	Local delivery of c-myc neutrally charged antisense oligonucleotides with transport catheter inhibits myointimal hyperplasia and positively affects vascular remodeling in the rabbit balloon injury model. Catheterization and Cardiovascular Interventions, 2001, 54, 247-256.	1.7	28
115	Arginine-rich cell-penetrating peptides facilitate delivery of antisense oligomers into murine leukocytes and alter pre-mRNA splicing. Journal of Immunological Methods, 2007, 325, 114-126.	1.4	28
116	Inhibition of HSV-1 ocular infection with morpholino oligomers targeting ICP0 and ICP27. Antiviral Research, 2009, 84, 131-141.	4.1	28
117	Binding of Antisense Phosphorothioate Oligonucleotides to Murine Lymphocytes Is Lineage Specific and Inducible. Antisense Research and Development, 1992, 2, 223-233.	3.1	27
118	Virus-specific antiviral treatment for controlling severe and fatal outbreaks of feline calicivirus infection. American Journal of Veterinary Research, 2008, 69, 23-32.	0.6	27
119	Selective changes in cytochrome P-450 and UDP-glucuronosyltransferase subpopulations following partial hepatectomy in rats. Toxicology and Applied Pharmacology, 1985, 78, 10-18.	2.8	26
120	Oligonucleotides in the treatment of leukemia. Hematological Oncology, 1994, 12, 9-14.	1.7	26
121	Blockade of viral interleukin-6 expression of Kaposi's sarcomaâ€“associated herpesvirus. Molecular Cancer Therapeutics, 2008, 7, 712-720.	4.1	26
122	Reduced Expression of CD45 Protein-tyrosine Phosphatase Provides Protection against Anthrax Pathogenesis. Journal of Biological Chemistry, 2009, 284, 12874-12885.	3.4	26
123	Alternative Splice Forms of CTLA-4 Induced by Antisense Mediated Splice-Switching Influences Autoimmune Diabetes Susceptibility in NOD Mice. Nucleic Acid Therapeutics, 2014, 24, 114-126.	3.6	26
124	Pharmacology and toxicology of phosphorothioate oligonucleotides in the mouse, rat, monkey and man. Toxicology Letters, 1995, 82-83, 425-430.	0.8	25
125	Novel site-specific systemic delivery of Rapamycin with perfluorobutane gas microbubble carrier reduced neointimal formation in a porcine coronary restenosis model. Catheterization and Cardiovascular Interventions, 2005, 64, 389-394.	1.7	25
126	Isolation and characterization of a new Vesivirus from rabbits. Virology, 2005, 337, 373-383.	2.4	24

#	Article	IF	Citations
127	First human experience with local delivery of novel antisense AVI-4126 with Infiltrator catheter in de novo native and restenotic coronary arteries: 6-month clinical and angiographic follow-up from AVAIL study. Cardiovascular Revascularization Medicine, 2007, 8, 230-235.	0.8	24
128	Delayed Time-to-Treatment of an Antisense Morpholino Oligomer Is Effective against Lethal Marburg Virus Infection in Cynomolgus Macaques. PLoS Neglected Tropical Diseases, 2016, 10, e0004456.	3.0	24
129	Transdermal Delivery of Antisense Oligonucleotides Can Induce Changes in Gene ExpressionIn Vivo. Oligonucleotides, 2001, 11, 1-6.	4.3	23
130	Targeted vascular delivery of antisense molecules using intravenous microbubbles. Cardiovascular Revascularization Medicine, 2006, 7, 25-33.	0.8	23
131	Inhibition of norovirus replication by morpholino oligomers targeting the 5â€²-end of the genome. Virology, 2008, 380, 328-337.	2.4	22
132	The turnover of tRNAs microinjected into animal cells. Nucleic Acids Research, 1978, 5, 3715-3730.	14.5	21
133	Regulation of zinc metallothionein II mRNA level in rat brain. Neurochemistry International, 1990, 17, 441-447.	3.8	21
134	Effects ofBCR-ABLAntisense Oligonucleotides (AS-ODN) on Human Chronic Myeloid Leukemic Cells: AS-ODN as Effective Purging Agents. Leukemia and Lymphoma, 1995, 20, 67-76.	1.3	20
135	Transdermal use of phosphorodiamidate morpholino oligomer AVI-4472 inhibits cytochrome P450 3A2 activity in male rats. Pharmaceutical Research, 2002, 19, 1465-1470.	3.5	20
136	Inhibition of infectious haematopoietic necrosis virus in cell cultures with peptide-conjugated morpholino oligomers. Journal of Fish Diseases, 2005, 28, 399-410.	1.9	20
137	Cellular Uptake of Neutral Phosphorodiamidate Morpholino Oligomers. Current Pharmaceutical Biotechnology, 2009, 10, 579-588.	1.6	20
138	Characterization of a variety of standard collagen substrates: Ultrastructure, uniformity, and capacity to bind and promote growth of neurons. In Vitro, 1981, 17, 540-552.	1.2	19
139	Tumor cell growth is inhibited by suppressing metallothionein-I synthesis. Cancer Letters, 1997, 116, 145-149.	7.2	19
140	Manipulation of Metallothionein Expression in the Regenerating Rat Liver Using Antisense Oligonucleotides. Biochemical and Biophysical Research Communications, 1998, 246, 711-718.	2.1	19
141	Systemic targeted delivery of antisense with perflourobutane gas microbubble carrier reduced neointimal formation in the porcine coronary restenosis model. Cardiovascular Radiation Medicine, 2003, 4, 152-159.	0.6	19
142	Inhibition of measles virus infections in cell cultures by peptide-conjugated morpholino oligomers. Virus Research, 2009, 140, 49-56.	2.2	18
143	Inhibition of hepatitis E virus replication by peptide-conjugated morpholino oligomers. Antiviral Research, 2015, 120, 134-139.	4.1	18
144	Microsomal cytochrome P-450 â€œHandprintsâ€• Five fractions from anion-exchange high-pressure liquid chromatography provide a rapid preliminary screen for selectivity in the induction and destruction of rat hepatic cytochrome P-450 subpopulations. Toxicology and Applied Pharmacology, 1985, 78, 1-9.	2.8	17

#	Article	IF	Citations
145	Antisense therapy for restenosis following percutaneous coronary intervention. Expert Opinion on Biological Therapy, 2005, 5, 79-89.	3.1	17
146	Lymphocytic Choriomeningitis Virus Infection in FVB Mouse Produces Hemorrhagic Disease. PLoS Pathogens, 2012, 8, e1003073.	4.7	17
147	Safety, tolerability, and pharmacokinetics of radavirsen (AVIâ€7100), an antisense oligonucleotide targeting influenza a M1/M2 translation. British Journal of Clinical Pharmacology, 2018, 84, 25-34.	2.4	17
148	Neuronal stimulation of non-neuronal (glial) cell proliferation: Lack of specificity between different regions of the nervous system. Developmental Brain Research, 1982, 3, 547-555.	1.7	16
149	Detection of vesicular exanthema of swine-like calicivirus in tissues from a naturally infected spontaneously aborted bovine fetus. Journal of the American Veterinary Medical Association, 2002, 220, 455-458.	0.5	16
150	Reaction between Metabolically Activated Acetaminophen and Phosphorothioate Oligonucleotides. Toxicology and Applied Pharmacology, 1995, 133, 53-63.	2.8	15
151	Inhibition of p53 expression by peptide-conjugated phosphorodiamidate morpholino oligomers sensitizes human cancer cells to chemotherapeutic drugs. Oncogene, 2012, 31, 1024-1033.	5.9	15
152	Effects of millimeter-wave radiation on monolayer cell cultures. II. Scanning and transmission electron microscopy. Bioelectromagnetics, 1981, 2, 141-150.	1.6	14
153	Antisense Oligonucleotide-Mediated Inhibition of Metallothionein Protein Synthesis in Neuroblastoma IMR 32 and Chang Liver Cells in Culture. NeuroSignals, 1992, 1, 57-64.	0.9	14
154	In vivo properties of an in situ forming gel for parenteral delivery of macromolecular drugs. Pharmaceutical Research, 1998, 15, 1189-1195.	3.5	14
155	Evidence of Enhanced Iron Excretion During Systemic Phosphorothioate Oligodeoxynucleotide Treatment. Journal of Toxicology: Clinical Toxicology, 2000, 38, 383-387.	1.5	14
156	Structural details of the human cytochrome P-450c gene. Archives of Biochemistry and Biophysics, 1987, 256, 397-401.	3.0	12
157	Induced IL-10 Splice Altering Approach to Antiviral Drug Discovery. Nucleic Acid Therapeutics, 2014, 24, 179-185.	3.6	12
158	Splicing in the immune system: potential targets for therapeutic intervention by antisense-mediated alternative splicing. Current Opinion in Molecular Therapeutics, 2009, 11, 124-32.	2.8	12
159	Complete vascular healing and sustained suppression of neointimal thickening after local delivery of advanced c-myc antisense at six months follow-up in a rabbit balloon injury model. Cardiovascular Radiation Medicine, 2002, 3, 26-30.	0.6	11
160	Transdermal delivery of phosphorodiamidate Morpholino oligomers across hairless mouse skin. International Journal of Pharmaceutics, 2004, 275, 217-226.	5.2	11
161	Peptide Conjugated Phosphorodiamidate Morpholino Oligomers Increase Survival of Mice Challenged with AmesBacillus anthracis. Nucleic Acid Therapeutics, 2012, 22, 316-322.	3.6	11
162	Depleting regulatory T cells with arginine-rich, cell-penetrating, peptide-conjugated morpholino oligomer targeting FOXP3 inhibits regulatory T-cell function. Cancer Gene Therapy, 2012, 19, 30-37.	4.6	11

#	Article	IF	Citations
163	Inhibition and Escape of SARS-CoV Treated with Antisense Morpholino Oligomers. Advances in Experimental Medicine and Biology, 2006, 581, 567-571.	1.6	11
164	Photoactivation of Vascular iNOS and Elevation of cGMP In Vivo: Possible Mechanism for Photovasorelaxation and Inhibition of Restenosis in an Atherosclerotic Rabbit ModelÂ¶. Photochemistry and Photobiology, 2000, 72, 579.	2.5	11
165	The development of broad-spectrum antiviral medical countermeasures to treat viral hemorrhagic fevers caused by natural or weaponized virus infections. PLoS Neglected Tropical Diseases, 2022, 16, e0010220.	3.0	11
166	Synergy of phenobarbital and 3-methylcholanthrene in â€œsuperinductionâ€•of cytochrome P-450c mRNA but not enzyme activity. Biochemical Pharmacology, 1987, 36, 3399-3403.	4.4	10
167	Antisense Oligonucleotide of c-<i>myc</i> Discriminates between Zinc- and Dexamethasone-Induced Synthesis of Metallothionem. Pharmacology, 1994, 48, 119-126.	2.2	10
168	The Cytotoxic Effects of Single-Stranded Telomere Mimics on OMA-BL1 Cells. Experimental Cell Research, 1999, 252, 41-49.	2.6	10
169	Development of Novel Bioanalytical Methods to Determine the Effective Concentrations of Phosphorodiamidate Morpholino Oligomers in Tissues and Cells. BioResearch Open Access, 2013, 2, 61-66.	2.6	10
170	Alternative splicing of the vitamin D receptor modulates target gene expression and promotes ligand-independent functions. Toxicology and Applied Pharmacology, 2019, 364, 55-67.	2.8	10
171	Alternative Splicing in the Nuclear Receptor Superfamily Expands Gene Function to Refine Endo-Xenobiotic Metabolism. Drug Metabolism and Disposition, 2020, 48, 272-287.	3.3	10
172	Phosphorodiamidate Morpholino Oligomers. , 2001, , .		10
173	Induction of cytochromes P450IA1 and P450IA2 as determined by solution hybridization. Biochemical Pharmacology, 1991, 41, 1719-1723.	4.4	9
174	Synthetic Antisense Oligonucleotide Probes the Essentiality of Metallothionein Gene. NeuroSignals, 1992, 1, 293-299.	0.9	9
175	Involvement of cytochrome P450 2E1-like isoform in the activation of N-nitrosobis(2-oxopropyl)amine in the rat nasal mucosa. European Journal of Cancer Part B, Oral Oncology, 1994, 30, 179-185.	0.9	9
176	Preparation of Oligomeric 2â€²-Deoxy-5-Fluorouridylate of Defined Length and Backbone Composition: A Novel Pro-Drug form of the Potent Anti-Cancer Drug 2â€²-Deoxy-5-Fluorouridylate. Nucleosides & Nucleotides, 1995, 14, 243-253.	0.5	9
177	Combination of antisense oligonucleotide and low-dose chemotherapy in hematological malignancies. Journal of Pharmacological and Toxicological Methods, 1997, 37, 229-235.	0.7	9
178	An Experimental Model for Interpreting Percutaneous Penetration of Oligonucleotides that Incorporates the Role of Keratinoctyes11This manuscript has been assigned Journal Series Number 12144, Agricultural Research Division, University of Nebraska. Journal of Investigative Dermatology, 1998, 111, 1166-1171.	0.7	9
179	Viral diversity and clonal evolution from unphased genomic data. BMC Genomics, 2014, 15, S17.	2.8	9
180	Targeted, Site-Specific, Delivery Vehicles of Therapeutics for COVID-19 Patients. Brief Review. Clinical and Applied Thrombosis/Hemostasis, 2020, 26, 107602962095491.	1.7	9

#	Article	IF	Citations
181	Remdesivir is efficacious in rhesus monkeys exposed to aerosolized Ebola virus. Scientific Reports, 2021, 11, 19458.	3.3	9
182	Eastern equine encephalitis virus rapidly infects and disseminates in the brain and spinal cord of cynomolgus macaques following aerosol challenge. PLoS Neglected Tropical Diseases, 2022, 16, e0010081.	3.0	9
183	HIV-1revAntisense Phosphorothioate Oligonucleotide Binding to Human Mononuclear Cells Is Cell Type Specific and Inducible. Antisense Research and Development, 1994, 4, 285-289.	3.1	8
184	Qualitative and quantitative measurements of oligonucleotides in gene therapy: Part I in vitro models. Journal of Pharmaceutical and Biomedical Analysis, 1997, 15, 857-873.	2.8	8
185	The molecular biology of the polycyclic aromatic hydrocarbon inducible cytochrome P-450; the past is prologue. BioEssays, 1986, 4, 15-19.	2.5	7
186	Prenatal and presymptomatic diagnosis of the marfan syndrome using fluorescence pcr and an automated sequencer. Prenatal Diagnosis, 1995, 15, 499-507.	2.3	7
187	Qualitative and quantitative measurements of oligonucleotides in gene therapy: Part II in vivo models. Journal of Pharmaceutical and Biomedical Analysis, 1997, 15, 1127-1135.	2.8	7
188	Oligonucleotide Enhanced Cytotoxicity of Idarubicin for Lymphoma Cells. Leukemia and Lymphoma, 2001, 42, 417-427.	1.3	7
189	Reduction in tamoxifen-induced CYP3A2 expression and DNA adducts using antisense technology. Molecular Carcinogenesis, 2006, 45, 118-125.	2.7	7
190	The Threat from Viruses. , 2018, , 45-76.		7
191	Antisense Targeting of cFLIP Sensitizes Activated T Cells to Undergo Apoptosis and Desensitizes Responses to Contact Dermatitis. Journal of Investigative Dermatology, 2009, 129, 1945-1953.	0.7	6
192	Morpholinos. , 2007, , 565-582.		5
193	Antisense treatment of caliciviridae: an emerging disease agent of animals and humans. Current Opinion in Molecular Therapeutics, 2002, 4, 177-84.	2.8	5
194	Antisense oligonucleotide development for the selective modulation of CYP3A5 in renal disease. Scientific Reports, 2021, 11, 4722.	3.3	4
195	Regulation of the proliferation of embryonic chick leptomeningeal cells in vitro by both contact inhibition and co-culture with CNS neurons. Journal of Neuroscience Research, 1982, 8, 523-534.	2.9	3
196	Chromatographic and spectral investigations on the in vivo metabolites of 6-nitrobenzo[a]pyrene. Journal of Chromatography A, 1988, 450, 325-336.	3.7	3
197	In Vivo Modulation of the Rat Cytochrome P450 1A1 by Double-Stranded Phosphorothioate Oligodeoxynucleotides. Toxicology and Applied Pharmacology, 1995, 135, 179-184.	2.8	3
198	In vivo growth inhibition of leukemia P388 by Metallothionein-I antisense oligodeoxyribonucleotide. Journal of Trace Elements in Experimental Medicine, 1998, 11, 1-4.	0.8	3

#	Article	IF	Citations
199	Local Application of Antisense for Prevention of Restenosis. , 2005, 106, 037-050.		3
200	A k-mer based transcriptomics approach for antisense drug discovery targeting the Ewingâ€™s family of tumors. Oncotarget, 2018, 9, 30568-30586.	1.8	3
201	Manipulation of zebrafish embryogenesis by phosphorodiamidate morpholino oligomers indicates minimal non-specific teratogenesis. Current Opinion in Molecular Therapeutics, 2005, 7, 104-8.	2.8	3
202	Patterns of Cellular Uptake and Effects on Cell Survival Using Antimetallothionein Oligodeoxyribonucleotide Conjugates in vitro. NeuroSignals, 1994, 3, 140-149.	0.9	2
203	Responses of Human Cells to PAH-Induced DNA Damage. Polycyclic Aromatic Compounds, 2002, 22, 771-780.	2.6	2
204	Continuous Infusion of Antisense Phosphorothioate Therapeutics. , 1996, 1, 201-212.		1
205	Pharmacokinetics and In Vivo Effects of a Six-Base Phosphorothioate Oligodeoxynucleotide with Anticancer and Hematopoietic Activities in Swine. Journal of Hematotherapy and Stem Cell Research, 2000, 9, 205-214.	1.8	1
206	Transdermal Delivery of Antisense Oligonucleotides. , 2005, 106, 255-270.		1
207	Molecular Basis of Resilience. , 2018, , .		1
208	Chimpanzee adenovirus type 3 vectored Ebola vaccine: expanding the field. Lancet Infectious Diseases, The, 2020, 20, 636-637.	9.1	1
209	The suppression of metallothionein synthesis inhibits the growth of leukemia P388 cells. , 1999, , 613-617.		1
210	Health and Medical Care in Ethiopia. New England Journal of Medicine, 1989, 320, 1149-1150.	27.0	0
211	T.P.2.10 Restoration of dystrophin expression in mdx mouse by peptide-conjugated antisense oligonucleotides. Neuromuscular Disorders, 2008, 18, 759.	0.6	0
212	Treatment of highly pathogenic filovirus infections using advanced antisense technology. Retrovirology, 2010, 7, .	2.0	0
213	Chemicals in theÂEnvironment. , 2018, , 141-168.		0
214	Eteplirsen. , 2018, , 257-279.		0
215	Regulating Resilience. , 2018, , 281-301.		0
216	Bacterial Infectious Disease Threat. , 2018, , 97-122.		0

#	Article	IF	Citations
217	Immune Defense. , 2018, , 169-193.		0
218	Active Oxygen Defenses. , 2018, , 195-222.		0
219	Functional Activation of Autologous Human Diabetic Stem Cells for Cell Therapy. , 0, , .		0
220	An advanced antisense for local and stent based delivery for prevention of restenosis. , 2005, , 381-391.		0
221	Antisense approach. , 2007, , 371-380.		0
222	Experimental Therapeutics: Antisense and Gene Therapy Cardiovascular Drugs. , 2014, , 1-10.		0
223	Experimental Therapeutics: Antisense and Gene Therapy Cardiovascular Drugs. , 2015, , 1067-1074.		0
224	Analog Genetics. , 2018, , 223-255.		0
225	CURE 2000. , 2018, , 123-139.		0
226	Social Entropy. , 2018, , 19-44.		0
227	Nonlinear Anomalies. , 2018, , 77-95.		0
228	RNA-based therapeutics--from design to the clinic. Current Opinion in Molecular Therapeutics, 2009, 11, 107.	2.8	0